Squamous Cell Carcinoma, Head And Neck Clinical Trial
Official title:
Pre-operative Mocetinostat (MGCD0103) and Durvalumab (MEDI4736) (PRIMED) for Squamous Cell Carcinoma of the Oral Cavity
This is a Phase 1 Window of Opportunity study to evaluate the pharmacodynamic and immune effects of pre-operative therapy with Mocetinostat and Durvalumab on patients with squamous cell carcinoma of the oral cavity.
This is a single center, open-label, non-randomized, pre-operative window of opportunity
study for patients with resectable squamous cell carcinoma of the oral cavity who are
considered suitable for curative-intent surgical resection, with pre-operative Mocetinostat
and Durvalumab.
This study will involve treatment with Mocetinostat and Durvalumab, tests and procedures done
for safety and the collection of blood samples for biomarker research. Tissue samples (fresh
biopsy or archival tissue) will also be collected for biomarker research and evaluation.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT02296684 -
Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma
|
Phase 2 | |
| Completed |
NCT03575598 -
Sitravatinib (MGCD516) and Nivolumab in Oral Cavity Cancer Window Opportunity Study
|
Early Phase 1 | |
| Completed |
NCT02277197 -
Ficlatuzumab and Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
|
Phase 1 | |
| Terminated |
NCT00903461 -
Safety and Efficacy of Radiation/Cetuximab Plus EGFR Antisense DNA for Head and Neck Squamous Cell Carcinoma
|
Phase 1 | |
| Active, not recruiting |
NCT02369458 -
Mitomycin C in Patients With Incurable p16 Positive Oropharyngeal and p16 Negative Head and Neck Squamous Cell Carcinoma (HNSCC) Resistant to Standard Therapies
|
Phase 2 | |
| Withdrawn |
NCT02649530 -
A Phase II Trial Evaluating WNT974 in Patients With Metastatic Head and Neck Squamous Cell Carcinoma
|
Phase 2 |